Queen discusses science and space for British Science Week
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
British-based company Allergy Therapeutics developed the vaccine which showed a significant reduction in the daily symptoms and use of relief medication compared to allergy sufferers on the placebo. Hay fever is one of the most common allergic conditions in the Western world that could affect up to 30 percent of the population, according to the World Health Organisation. Manuel Llobet, CEO at Allergy Therapeutics, stated: “We are delighted to announce these results demonstrating a clear treatment effect from our novel, short-course immunotherapy targeting grass pollen allergies.
“Grass pollen is one of the most common causes of seasonal allergic rhinitis in the Western world.
“Debilitating symptoms can affect so many aspects of life and new treatment options are needed.
“The group used a groundbreaking study design that brought state-of-the-art learnings in allergy field trial methodology to examine multiple endpoints and will enable the potential for extensive biomarker analysis.
“Significantly, the results will enable us to optimally design the upcoming pivotal G306 Phase 3 field trial, maximising the chances of success and supporting our regulatory plans for entry into the US.
“I am grateful for the hard work and effort put into this trial by our team at Allergy Therapeutics and everyone across the multiple trial sites, who kept the trial on course despite the challenges faced by the continuing COVID-19 pandemic.
“I would also like to thank the trial participants, who are vital to our research developing novel, innovative allergy immunotherapies with the potential to transform patients’ lives.”
More than 100 patients took part in the Phase 2 trials which took place in 14 sites across Germany and the US.
Two short courses of 6 injections were trialled, one over six weeks, the other over 14 weeks.
Both treatment groups produced a significant difference between them and the placebo group; 29.1 percent and 36.8 percent for the six and 14 weeks respectively.
Further analysis of the trials is now under way and will be submitted for peer-reviewed publication and presentation at upcoming key conferences.
The groundbreaking vaccine is expected to enter Phase 3 trials in 2022.
Sandeep Garcha, 24, a severe hay fever sufferer, said: “I’m excited by the prospect of a vaccine.
“Hay fever seems to start earlier and earlier each year for me which can affect my day-to-day living for several months of the year.
“It seems strange that we haven’t solved this sooner!”
Hay fever is caused by an allergy to pollen which can lead to flu-like symptoms including sneezing, a runny nose, and itchy eyes.
While it can often be controlled using over-the-counter medication from your pharmacist, some more severe cases require prescription medication.
Hay fever can affect people of all ages although it usually begins in childhood or during the teenage years.
The allergy is more common in boys than girls but in adults, men and women are equally affected.
Doctors warn you are more likely to develop hay fever if you have a family history of allergies, particularly asthma or eczema.
Despite not posing a serious threat to health, it can have a negative impact on a person’s quality of life.
People with very severe hay fever often find that it can disrupt their productivity at school or work.
Allergy Therapeutics hope this vaccine breakthrough will revolutionise allergy treatment and ease the suffering of millions.
Source: Read Full Article